Todd Harris Sells 600 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 600 shares of the stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $24.01, for a total value of $14,406.00. Following the sale, the chief executive officer now owns 1,477,873 shares of the company’s stock, valued at $35,483,730.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Todd Harris also recently made the following trade(s):

• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total value of $138,518.38.

Tyra Biosciences Price Performance

TYRA opened at $23.40 on Friday. The stock has a market capitalization of $1.24 billion, a P/E ratio of -13.93 and a beta of 1.01. The company’s 50 day simple moving average is $21.55 and its 200-day simple moving average is $18.84. Tyra Biosciences, Inc. has a one year low of $10.38 and a one year high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.09. As a group, analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Thursday, August 8th. Oppenheimer upped their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Finally, Piper Sandler started coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Institutional Trading of Tyra Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the period. Wellington Management Group LLP lifted its holdings in Tyra Biosciences by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the period. Bank of New York Mellon Corp lifted its holdings in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after buying an additional 14,352 shares during the period. HighVista Strategies LLC bought a new position in Tyra Biosciences in the second quarter valued at approximately $257,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in Tyra Biosciences during the 1st quarter worth $977,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.